

	Patient Population	Pre-clinical	Phase 1/2	Phase 3	Regulatory Approval
Setmelanotide <i>daily injection</i>	Acquired hypothalamic obesity (4 years of age and older)				US, EU
	Bardet-Biedl syndrome or biallelic POMC, PCSK1 or LEPR deficiency (2 years of age and older)*				US, EU, UK
Setmelanotide <i>daily injection</i> [^]	Congenital hypothalamic obesity [†]				
	Prader-Willi syndrome				
Bivamelagon <i>daily oral formulation</i> [^]	Acquired hypothalamic obesity				
RM-718 <i>weekly injection</i> [^]	Acquired hypothalamic obesity				
	Prader-Willi syndrome				
Pre-clinical	Congenital hyperinsulinism (CHI)				

Complete Ongoing

*Approved in Canada (6 years of age and older)

[^]Currently being studied as

[†]Setmelanotide is being studied in a proof-of-concept substudy of the Phase 3 TRANSCEND trial

LEPR, leptin receptor; MC4R, melanocortin-4 receptor; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin.